2025 annual financial data
BridgeBio Oncology Therapeutics 2025 Operating cash flow margin
Direct answer
Operating cash flow margin was Not calculable.
Operating income was -145,819,000 USD and net income was -134,044,000 USD.
Operating cash flow was -113,894,000 USD.
Get free BridgeBio Oncology Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -145,819,000 USD
- Net income
- -134,044,000 USD
- Operating cash flow
- -113,894,000 USD